RxDoctor Payments Data

Ayesha Nasir, MD

Family Medicine · Raleigh, NCNPI 1215109509

Payments from drug & device makers

$1,237in general payments, 2019–2025

Across 66 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$304
  • AbbVie$296
  • Merz North America, Inc.$88
  • Exact Sciences$78
  • Gilead$77
  • Pfizer$75
  • plus $317 from 16 others

What the payments were for

  • Food & beverage$1,237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,237 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$62,022
Medicare patients
140
Services billed
1,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$49,546
MounjaroTirzepatide36$41,540
TrulicityDulaglutide14$32,537
EliquisApixaban22$24,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,088
AbrysvoRsv Vacc, Pref A And Pref B/Pf50$15,991
Tresiba Flextouch U-200Insulin Degludec17$13,989
XareltoRivaroxaban18$13,342
Tresiba Flextouch U-100Insulin Degludec16$10,680
FarxigaDapagliflozin Propanediol18$10,175
VyvanseLisdexamfetamine Dimesylate11$4,009
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$3,915
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,539
Atorvastatin Calcium251$2,585
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf36$2,517

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$16$74,07850 claims
Novo NordiskOzempic$304$49,54647 claims
PfizerEliquis, Abrysvo$75$40,50572 claims
Johnson & JohnsonXarelto$35$13,34218 claims
AstraZenecaFarxiga$27$10,17518 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$11$4,00911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →